Wednesday, May 28, 2025

EEIC Partners with InfyPower to Accelerate Smart, Sustainable EV Charging in the UAEEmirates Electrical & Instrumentation Company (EEIC), a leader in industrial solutions and instrumentation services in the UAE, has partnered with InfyPower, a global leader in the Electrical Vehicles Charging and Energy Storage Industry. Through this partnership, EEIC becomes the exclusive agent of Infypower in the UAE, combining their global engineering expertise with EEIC’s regional legacy to offer scalable, intelligent EV charging and Energy Storage solutions. The partnership is being showcased during the World Utilities Congress 2025 in Abu Dhabi, where both companies are presenting their collaboration and breakthrough technologies alike. As part of the exhibition, one of InfyPower’s advanced EV charger models is being displayed at the EEIC stand, highlighting the joint commitment to building a clean, connected future for mobility infrastructure in the UAE. InfyPower’s EV chargers offer a distinct advantage with their ability to operate both off-grid and on-grid - offering unique flexibility for deployment across both urban and remote environments. This hybrid capability directly supports the UAE’s Net Zero 2050 Strategy, responding to the growing demand for green transportation and clean energy innovation. The integration of InfyPower’s solutions into EEIC’s offerings reinforces a shared mission to drive future-ready, energy-efficient infrastructure across the region. Joseph Mazzotta, Sales Director EMEA at InfyPower, commented, “Partnering with EEIC represents a major milestone for us as we expand our footprint into the Middle East. Our mission is to be a leading provider of EV charging and energy storage power solutions, and a respected technical benchmark and pioneer in the power industry. This partnership allows us to bring that vision to life - delivering reliable, flexible, and future-oriented charging solutions tailored to the UAE’s needs.” Hagop Dermosessian, General Manager, at Emirates Electrical & Instrumentation Company (EEIC) & GCG Engineering Services, said, “Our collaboration with InfyPower marks a new chapter in our efforts to introduce sustainable, intelligent technologies to the UAE market. By offering state-of-the-art EV chargers with both off-grid and on-grid functionality, we are equipping industries and communities with the tools to embrace clean mobility and reduce environmental impact. This partnership reinforces EEIC’s commitment to innovation and long-term value creation across the region.” Together, EEIC and InfyPower are advancing the UAE’s clean energy transition by accelerating the adoption of smart EV infrastructure - supporting the country’s net-zero ambitions and broader vision for sustainable urban development. About InfyPower Shenzhen Infypower Co., Ltd. is a high-tech company professionally engaged in power supply and power system solutions for the renewable energy industry. We are professional in power electronic technology, focus on the electric vehicle power solutions, our products include charger modules, charging system controllers, charging station management systems, and vehicle mounted power supplies etc. Infypower focused on Infy Inside strategy, is willing to be the foundation, as a worry free support for the customer.Industry Appliances, Electrical, and Electronics Manufacturing About EEIC Established in 2002, Emirates Electrical & Instrumentation Company (EEIC) – A Ghobash Group Enterprise, takes pride in being a leading Engineering, Procurement and Construction (EPC) Company in the UAE. With over 500 specialists and cutting-edge technology, EEIC excels in mechanical, electrical, instrumentation and control systems, undertaking complex projects across various sectors such as Oil & gas, Energy, Power, Utilities, Water Treatment & Management, and Smart Infrastructure. EEIC's clients include ADNOC, government entities, semi-government organizations, and leading EPC contractors. The company is focused on renewable sustainable energy solutions, aiming to be a top contractor and employer in its industry. For more information, visit eeic-uae.com or write to info@eeic-uae.com. You can also follow EEIC on LinkedIn. Permalink https://www.aetoswire.com/en/news/2805202546999 Contacts Tony Hamad Group Marketing Director +971 45 961 800

 Emirates Electrical & Instrumentation Company (EEIC), a leader in industrial solutions and instrumentation services in the UAE, has partnered with InfyPower, a global leader in the Electrical Vehicles Charging and Energy Storage Industry.


Through this partnership, EEIC becomes the exclusive agent of Infypower in the UAE, combining their global engineering expertise with EEIC’s regional legacy to offer scalable, intelligent EV charging and Energy Storage solutions.


The partnership is being showcased during the World Utilities Congress 2025 in Abu Dhabi, where both companies are presenting their collaboration and breakthrough technologies alike. As part of the exhibition, one of InfyPower’s advanced EV charger models is being displayed at the EEIC stand, highlighting the joint commitment to building a clean, connected future for mobility infrastructure in the UAE.


InfyPower’s EV chargers offer a distinct advantage with their ability to operate both off-grid and on-grid - offering unique flexibility for deployment across both urban and remote environments. This hybrid capability directly supports the UAE’s Net Zero 2050 Strategy, responding to the growing demand for green transportation and clean energy innovation. The integration of InfyPower’s solutions into EEIC’s offerings reinforces a shared mission to drive future-ready, energy-efficient infrastructure across the region.


Joseph Mazzotta, Sales Director EMEA at InfyPower, commented, “Partnering with EEIC represents a major milestone for us as we expand our footprint into the Middle East. Our mission is to be a leading provider of EV charging and energy storage power solutions, and a respected technical benchmark and pioneer in the power industry. This partnership allows us to bring that vision to life - delivering reliable, flexible, and future-oriented charging solutions tailored to the UAE’s needs.”


Hagop Dermosessian, General Manager, at Emirates Electrical & Instrumentation Company (EEIC) & GCG Engineering Services, said, “Our collaboration with InfyPower marks a new chapter in our efforts to introduce sustainable, intelligent technologies to the UAE market. By offering state-of-the-art EV chargers with both off-grid and on-grid functionality, we are equipping industries and communities with the tools to embrace clean mobility and reduce environmental impact. This partnership reinforces EEIC’s commitment to innovation and long-term value creation across the region.”


Together, EEIC and InfyPower are advancing the UAE’s clean energy transition by accelerating the adoption of smart EV infrastructure - supporting the country’s net-zero ambitions and broader vision for sustainable urban development.


About InfyPower


Shenzhen Infypower Co., Ltd. is a high-tech company professionally engaged in power supply and power system solutions for the renewable energy industry. We are professional in power electronic technology, focus on the electric vehicle power solutions, our products include charger modules, charging system controllers, charging station management systems, and vehicle mounted power supplies etc. Infypower focused on Infy Inside strategy, is willing to be the foundation, as a worry free support for the customer.Industry


Appliances, Electrical, and Electronics Manufacturing


About EEIC


Established in 2002, Emirates Electrical & Instrumentation Company (EEIC) – A Ghobash Group Enterprise, takes pride in being a leading Engineering, Procurement and Construction (EPC) Company in the UAE. With over 500 specialists and cutting-edge technology, EEIC excels in mechanical, electrical, instrumentation and control systems, undertaking complex projects across various sectors such as Oil & gas, Energy, Power, Utilities, Water Treatment & Management, and Smart Infrastructure. EEIC's clients include ADNOC, government entities, semi-government organizations, and leading EPC contractors. The company is focused on renewable sustainable energy solutions, aiming to be a top contractor and employer in its industry.


For more information, visit eeic-uae.com or write to info@eeic-uae.com. You can also follow EEIC on LinkedIn.



Permalink

https://www.aetoswire.com/en/news/2805202546999


Contacts

Tony Hamad


Group Marketing Director


+971 45 961 800  

Perma-Pipe International Holdings, Inc. Announces New Contract Award in Qatar


 SPRING, Texas 

(BUSINESS WIRE) -- Perma-Pipe International Holdings, Inc. (Nasdaq: PPIH) today announced that it has received its first project award to be executed in Qatar since the announcement of the intent to mobilize there.


The project will be for USD $2.4 million and will utilize Perma-Pipe’s fabrication capabilities and the XTRU-THERM® insulation system, a spray-applied polyurethane foam jacketed with a high-density polyethylene casing.


Adham Sharkawy, Senior Vice President of Perma-Pipe’s MENA region, remarked, “In response to this important award, we will begin executing the project from a temporary facility in Doha, ensuring timely delivery and uninterrupted service to our client. Simultaneously, we are advancing the construction of our permanent facility in Qatar, which will serve as a long-term base for our regional operations. We are deeply grateful to our customers for their continued trust and confidence in Perma-Pipe’s capabilities.”


Saleh Sagr, President, commented, “Expanding in Doha has been an important goal for Perma-Pipe and is a key step in expanding our presence in the MENA region. Our plan shows our strong commitment to the Qatari market and supports our goal for steady growth and local investment. The new facility will be an important base for our work in Qatar and will help us serve markets in Southeast Asia.”


David Mansfield, CEO, stated, “This award signifies a major milestone for Perma-Pipe and aligns with our strategic expansion into Qatar. This project not only demonstrates the strength of our solutions but also plays a vital role in solidifying our position in the market. We are confident that this achievement will fuel our continued growth and further enhance our reputation as a trusted leader in the industry.”


Perma-Pipe International Holdings, Inc.


Perma-Pipe International Holdings, Inc. (Nasdaq: PPIH) is a global leader in pre-insulated piping and leak detection systems for oil and gas, district heating and cooling, and other applications. It uses its extensive engineering and fabrication expertise to develop piping solutions that solve complex challenges regarding the safe and efficient transportation of many types of liquids. In total, Perma-Pipe has operations at fourteen locations in six countries.


Forward-Looking Statements


Certain statements and other information contained in this press release that can be identified by the use of forward-looking terminology constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbors created thereby, including, without limitation, statements regarding the expected future performance and operations of the Company. These statements should be considered as subject to the many risks and uncertainties that exist in the Company's operations and business environment. Such risks and uncertainties include, but are not limited to, the following: (i) the impact of the coronavirus ("COVID-19") on the Company's results of operations, financial condition and cash flows; (ii) fluctuations in the price of oil and natural gas and its impact on the customer order volume for the Company's products; (iii) the Company's ability to comply with all covenants in its credit facilities; (iv) the Company’s ability to repay its debt and renew expiring international credit facilities; (v) the Company’s ability to effectively execute its strategic plan and achieve profitability and positive cash flows; (vi) the impact of global economic weakness and volatility; (vii) fluctuations in steel prices and the Company’s ability to offset increases in steel prices through price increases in its products; (viii) the timing of order receipt, execution, delivery and acceptance for the Company’s products; (ix) decreases in government spending on projects using the Company’s products, and challenges to the Company’s non-government customers’ liquidity and access to capital funds; (x) the Company’s ability to successfully negotiate progress-billing arrangements for its large contracts; (xi) aggressive pricing by existing competitors and the entrance of new competitors in the markets in which the Company operates; (xii) the Company’s ability to purchase raw materials at favorable prices and to maintain beneficial relationships with its suppliers; (xiii) the Company’s ability to manufacture products free of latent defects and to recover from suppliers who may provide defective materials to the Company; (xiv) reductions or cancellations of orders included in the Company’s backlog; (xv) the Company's ability to collect an account receivable related to a project in the Middle East; (xvi) risks and uncertainties related to the Company's international business operations; (xvii) the Company’s ability to attract and retain senior management and key personnel; (xviii) the Company’s ability to achieve the expected benefits of its growth initiatives; (xix) the Company’s ability to interpret changes in tax regulations and legislation; (xx) the Company's ability to use its net operating loss carryforwards; (xxi) reversals of previously recorded revenue and profits resulting from inaccurate estimates made in connection with the Company’s percentage-of-completion revenue recognition; (xxii) the Company’s failure to establish and maintain effective internal control over financial reporting; and (xxiii) the impact of cybersecurity threats on the Company’s information technology systems. Shareholders, potential investors and other readers are urged to consider these factors carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such forward-looking statements. The forward-looking statements made herein are made only as of the date of this press release and we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. More detailed information about factors that may affect our performance may be found in our filings with the Securities and Exchange Commission, which are available at https://www.sec.gov and under the Investor Center section of our website (http://investors.permapipe.com).


 


View source version on businesswire.com: https://www.businesswire.com/news/home/20250527587388/en/



Permalink

https://www.aetoswire.com/en/news/2805202546975


Contacts

Perma-Pipe International Holdings, Inc.

David Mansfield, CEO


Perma-Pipe Investor Relations

847.929.1200

investor@permapipe.com

FES Super Extends Partnership with SS&C

 WINDSOR, Conn. - Wednesday, 28. May 2025 AETOSWire 



(BUSINESS WIRE) -- SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced the Fire and Emergency Services Superannuation Fund (“FES Super”) has signed a long-term agreement to extend its existing partnership with SS&C. The renewal reinforces SS&C’s leadership and continued growth in the Australian superannuation market, following several recent strategic wins in the region.


FES Super leverages SS&C Bluedoor, a cloud-hosted registry platform, to manage its administration needs. The platform enables real-time automation and straight-through processing, helping streamline operations and improving member experiences. SS&C also provides member digital and reporting services to the fund.


“Our top priority is acting in the best interests of our members,” said Adrian Rutter, Fund Secretary at FES Super. “SS&C’s flexible, customizable tools and consistent service enable us to continue doing just that. By leveraging Bluedoor’s integration capabilities and cloud-native services, we can efficiently deliver to our members a modern, high-quality user experience.”


Bluedoor is the foundation of SS&C Global Investor & Distribution Solutions’ (GIDS) digital operating model for superannuation. The technology supports defined contribution, defined benefit and pension products, and enables funds like FES Super team to access and process data in real time.


“We are proud to renew our deep-rooted partnership with FES Super,” said Shaun McKenna, Head of GIDS Australia SS&C. “The fund has grown significantly since our initial engagement nearly 15 years ago. We look forward to working with the FES team to help deliver a superior member experience.”


The announcement follows recent client wins and renewals in Australia across both superannuation and wealth sectors, reflecting strong market demand for SS&C’s modern, cloud-based solutions. With increasing pressure on super funds to modernize and scale, SS&C is positioned as a strategic partner of choice for forward-thinking funds seeking operational efficiency and member-centric innovation.


About FES Super


The Fire and Emergency Services Superannuation Fund (FES Super) is the superannuation fund for employees of the Department of Fire and Emergency Services of Western Australia and some associated employers. FES Super provides superannuation and other benefits (such as retirement products) for members employed by or formerly employed by the Department of Fire and Emergency Services (DFES) and associated employers including the United Professional Firefighter’s Union of Western Australia, the Western Australian Volunteer Fire and Rescue Services Association (Inc.) and the Superannuation Board itself. FES Super’s purpose is to help its members achieve financial security in retirement. Learn more at https://www.fessuper.com.au/


About SS&C Technologies


SS&C is a global provider of services and software for the financial services and healthcare industries. Founded in 1986, SS&C is headquartered in Windsor, Connecticut, and has offices around the world. More than 22,000 financial services and healthcare organizations, from the world's largest companies to small and mid-market firms, rely on SS&C for expertise, scale and technology.


Additional information about SS&C (Nasdaq: SSNC) is available at www.ssctech.com.


Follow SS&C on X, LinkedIn and Facebook.


 


View source version on businesswire.com: https://www.businesswire.com/news/home/20250527377302/en/



Permalink

https://www.aetoswire.com/en/news/2805202546976


Contacts

Brian Schell

Chief Financial Officer

SS&C Technologies

Tel: +1-816-642-0915

E-mail:

InvestorRelations@sscinc.com


Justine Stone

Investor Relations

SS&C Technologies

Tel: +1-212-367-4705

E-mail:

InvestorRelations@sscinc.com


Media Contacts

Prosek

Sam Gentile

Tel: +1-646-818-9195

Email: pro-SSC@prosek.com


 

Galderma Buys Back Shares Worth CHF 233 Million in the Context of Accelerated Bookbuild Offering


 ZUG, Switzerland 

Ad hoc announcement pursuant to Art. 53 LR


(BUSINESS WIRE) -- Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that it has agreed to repurchase 2.38 million shares at a price of CHF 97.75 per share for a total consideration of CHF 232.5 million in the context of the accelerated bookbuild offering (“ABO”) of Galderma shares by Sunshine SwissCo GmbH (“EQT”), Abu Dhabi Investment Authority and Auba Investment Pte. Ltd. launched yesterday evening. The repurchase was made at the same price per share determined by the bookbuilding offering.


The repurchase, which is expected to settle on June 2, is being financed by Galderma’s existing liquidity on hand and will not affect the company’s ability to deliver on its strategic and financing priorities.


The shares will be held in treasury for future use in connection with Galderma's employee participation plans, business development opportunities and/or treasury management.


 


“The repurchase of shares announced today is a testament to the confidence of the Executive Committee and the Board of Directors in the performance fundamentals and the attractive shareholder value creation outlook of Galderma. The participation in the offering reflects our continued focus on disciplined capital allocation, commitment to attractive shareholder returns and our confidence in Galderma’s strong cash generation and investment grade balance sheet.”


 


FLEMMING ØRNSKOV, M.D., MPH


CHIEF EXECUTIVE OFFICER


GALDERMA


 


 


Following the closing of the ABO, the free float in Galderma’s shares is expected to increase from 41.8% to 49.8%.


About Galderma

Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com.


Forward-looking statements


Certain statements in this announcement are forward-looking statements. Forward-looking statements are statements that are not historical facts and may be identified by words such as "plans", "targets", "aims", " believes", "expects", "anticipates", "intends", "estimates", "will", "may", "continues", "should" and similar expressions. These forward-looking statements reflect, at the time, Galderma's beliefs, intentions and current targets/ aims concerning, among other things, Galderma's results of operations, financial condition, industry, liquidity, prospects, growth and strategies and are subject to change. The estimated financial information is based on management's current expectations and is subject to change. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial consequences of the plans and events described herein. Actual results may differ from those set forth in the forward-looking statements as a result of various factors (including, but not limited to, future global economic conditions, changed market conditions, intense competition in the markets in which Galderma operates, costs of compliance with applicable laws, regulations and standards, diverse political, legal, economic and other conditions affecting Galderma’s markets, and other factors beyond the control of Galderma). Neither Galderma nor any of their respective shareholders (as applicable), directors, officers, employees, advisors, or any other person is under any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. You should not place undue reliance on forward-looking statements, which speak of the date of this announcement. Statements contained in this announcement regarding past trends or events should not be taken as a representation that such trends or events will continue in the future. Some of the information presented herein is based on statements by third parties, and no representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, reasonableness, accuracy, completeness or correctness of this information or any other information or opinions contained herein, for any purpose whatsoever. Except as required by applicable law, Galderma has no intention or obligation to update, keep updated or revise this announcement or any parts thereof.


 


View source version on businesswire.com: https://www.businesswire.com/news/home/20250527014109/en/



Permalink

https://www.aetoswire.com/en/news/2805202546983


Contacts

For further information:


Christian Marcoux, M.Sc.

Chief Communications Officer

christian.marcoux@galderma.com

+41 76 315 26 50


Richard Harbinson

Corporate Communications Director

richard.harbinson@galderma.com

+41 76 210 60 62


Emil Ivanov

Head of Strategy, Investor Relations, and ESG

emil.ivanov@galderma.com

+41 21 642 78 12


Jessica Cohen

Investor Relations and Strategy Director

jessica.cohen@galderma.com

+41 21 642 76 43

BeOne Medicines Launches Following Redomiciliation to Switzerland, Marking a New Chapter in Global Oncology

 BeOne well-positioned to deliver transformative treatments to patients worldwide with powerful oncology portfolio, pioneering clinical development approach, and expanded global manufacturing and commercial capabilities

Redomiciliation to Switzerland bolsters Company’s presence in leading global biopharmaceutical hub, marks next step in becoming a diversified biotechnology company focused on oncology

 


(BUSINESS WIRE)--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company formerly known as BeiGene, Ltd., today announced its new name and redomiciliation to Switzerland are officially in effect, marking a significant milestone in the Company’s evolution.


“BeOne represents more than a name change—it’s not only a reflection of who we are today as a leading global oncology company, but also our ambition to redefine what’s possible in oncology as we unite patients, families, scientists, physicians, governments, and other oncology public health stakeholders around the world in our shared mission against cancer,” said John V. Oyler, Co-Founder, Chairman and CEO at BeOne. “While I know that our work is not done, I am extremely proud of the progress we have made with the explosive growth of BRUKINSA as the backbone of our hematology franchise, the expansion of our PD-1 inhibitor, TEVIMBRA, and our potentially transformative oncology pipeline of more than 50 investigational assets, one of the most prolific in the industry. After 15 years of relentless innovation and strategic investment to boost our internal global capabilities, we are just getting started, and I look forward to working together as BeOne.”


The new name and redomiciliation to Switzerland from the Cayman Islands were approved by shareholders on April 28. The transition to the BeOne name across the Company’s worldwide operations on six continents will happen in phases. The redomiciliation to Switzerland strengthens BeOne’s presence and deepens its roots in a global biopharmaceutical hub, further enabling its growth strategy of bringing innovative medicines to patients around the world.


Industry-Leading Innovation and Global Scale


BeOne has built a differentiated and sustainable advantage through strategic investments to bolster its internal research, clinical development, and manufacturing capabilities. This unique model harnesses time and cost efficiencies to improve patient access, enables close oversight to enforce high standards across R&D and manufacturing, and safeguards our operational resilience for long-term growth. BRUKINSA has the broadest label in its treatment class and leads in new patient starts across all of its approved indications in the U.S. It also is the cornerstone of BeOne’s hematology franchise as a foundational treatment alongside late-stage BCL2 inhibitor sonrotoclax and potential first-in-class BTK protein degrader, BGB-16673, which was developed from the Company’s proprietary CDAC platform. BeOne also is focused on building future solid tumor franchises in breast, lung, and gastrointestinal cancers. By leveraging its platforms in multi-specific antibodies, protein degraders and antibody-drug conjugates, the Company is positioned to transform the future of oncology treatment.


BeOne’s entrepreneurial research team, comprising more than 1,100 colleagues, advanced 13 new molecular entities into the clinic in 2024 alone, outpacing even the largest pharmaceutical companies. Further, its nearly 3,700-strong clinical development team has active or planned trials across more than 45 countries and regions, accelerating early-stage innovation through its “Fast to Proof-of-Concept” approach. To date, the Company has enrolled more than 25,000 patients in more than 170 trials, delivering speed and cost advantages that set it apart from industry peers.


In addition, BeOne continues to expand its global manufacturing network with its $800 million flagship clinical R&D and manufacturing facility at the Princeton West Innovation Campus in Hopewell, N.J. This state-of-the-art site enables scalable production capacity to support the Company’s rapidly growing pipeline, operational resilience, and global ambitions.


About BeOne


BeOne Medicines, formerly known as BeiGene, is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. With a growing global team of more than 11,000 colleagues spanning six continents, the Company is committed to radically improving access to medicines for far more patients who need them. To learn more about BeOne, please visit www.beonemedicines.com and follow us on LinkedIn, X, Facebook and Instagram.


Forward-Looking Statements


This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding BeOne’s ability to deliver transformative treatments to patients worldwide; the potential and future success of BeOne’s oncology pipeline; BeOne’s presence in Switzerland and its ability to enable further growth; the sustainable advantage of BeOne’s strategic investments and its ability to improve patient access; the future long-term growth of the Company; BeOne’s ability to transform the future of oncology treatment; and BeOne’s plans, commitments, aspirations and goals under the caption “About BeOne”. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeOne’s ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; BeOne’s ability to achieve commercial success for its marketed medicines and drug candidates, if approved; BeOne’s ability to obtain and maintain protection of intellectual property for its medicines and technology; BeOne’s reliance on third parties to conduct drug development, manufacturing, commercialization, and other services; BeOne’s limited experience in obtaining regulatory approvals and commercializing pharmaceutical products; BeOne’s ability to obtain additional funding for operations and to complete the development of its drug candidates and maintain profitability; and those risks more fully discussed in the section entitled “Risk Factors” in BeOne’s most recent quarterly report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in BeOne’s subsequent filings with the U.S. Securities and Exchange Commission. All information in this press release is as of the date of this press release, and BeOne undertakes no duty to update such information unless required by law.


To access BeOne media resources, please visit our Newsroom.


 


View source version on businesswire.com: https://www.businesswire.com/news/home/20250526273239/en/



Permalink

https://www.aetoswire.com/en/news/2705202546965


Contacts

Investor Contact

Liza Heapes

+1 857-302-5663

ir@beonemed.com


Media Contact

Kyle Blankenship

+1 667-351-5176

media@beonemed.com

Rigaku Completes New Building at Yamanashi Plant

 Dramatic 2.7-fold increase in floor space to serve global demand


(BUSINESS WIRE)--Rigaku Corporation, a global solution partner in X-ray analytical technologies and a Group company of Rigaku Holdings Corporation (headquarters: Akishima, Tokyo; President and CEO: Jun Kawakami; hereinafter “Rigaku”) completed an additional manufacturing building (hereinafter “the New Building”) at Yamanashi Plant, Rigaku’s main production facility. The facility was established to serve as the center of Rigaku’s production framework, in anticipation of global business growth and expansion in product demand.

Doubling of production capacity: a strategic base to support Rigaku’s growth

Demand for X-ray analytical solutions has soared in recent years, both in Japan and worldwide. To respond to growing demand, Rigaku implemented this expansion with two key objectives in mind.

One objective is to further reinforce the Company’s ability to serve the needs of rapidly growing fields such as semiconductors and electronic components; batteries and battery materials; and life sciences. The other objective is to dramatically expand Rigaku’s production capacity for the components that support the Company’s product lineup generally. The components are the crystallization of Rigaku’s core technologies and the wellspring of its competitive strength.

To accomplish the two objectives described above, Rigaku plans to double its overall manufacturing capacity by 2027 (compared with 2022, unit basis). Rigaku aims to achieve this goal by expanding production space, through the construction of the New Building at Yamanashi Plant in addition to the expansion provided by Osaka Plant and external partners, and by shortening lead time to reinforce its supply chain.


Yamanashi Plant: Advancing as a Comprehensive Manufacturing Base

With the New Building’s completion, Yamanashi Plant’s floor space has expanded dramatically, almost tripling (2.7x) from 8,500 sqm to 23,000 sqm. Processes for manufacturing, assembly and shipping of X-ray diffraction systems, formerly distributed between Yamanashi and Tokyo, are now concentrated in spacious Yamanashi Plant, delivering a quantum leap in operational efficiency and ensuring stable supply of high-quality products.

Rigaku is also advancing proving tests for automation of production processes at Yamanashi Plant. The Company’s aim is to transform the Plant into a “smart factory” that achieves excellence in both efficiency and quality.


An eco-friendly “plant in harmony with nature”

Rigaku used eco-friendly construction methods to erect the New Building, taking care to reduce CO2 emissions. To minimize energy waste, the facility is outfitted with high-efficiency equipment and solar-power generation systems. The New Building is a “plant in harmony with nature,” contributing to the achievement of a sustainable society by reducing environmental impact.


Jun Kawakami, President and CEO of Rigaku, offered the following comment:

With this major floor space expansion, Rigaku is boosting manufacturing capacity and enhancing product quality to support its substantial growth. It also strengthens our ability to produce the components of our products, which are the foundation of Rigaku's competitive advantage. This facility is the key to ensuring that our existing customers continue to choose Rigaku, as well as helping Rigaku acquire new customers globally.


The New Building is slated to begin operation in early June, gradually strengthening Rigaku’s production framework.


About the Rigaku Group

Since its establishment in 1951, the engineering professionals of the Rigaku group have been dedicated to benefiting society with leading-edge technologies, notably including its core fields of X-ray and thermal analysis. With a market presence in over 90 countries and some 2,000 employees from 9 global operations, Rigaku is a solution partner in industry and research analysis institutes. Our overseas sales ratio has reached approximately 70% while sustaining an exceptionally high market share in Japan. Together with our customers, we continue to develop and grow. As applications expand from semiconductors, electronic materials, batteries, environment, resources, energy, life science to other high-tech fields, Rigaku realizes innovations “To Improve Our World by Powering New Perspectives.”

For details, please visit rigaku-holdings.com/english



View source version on businesswire.com: https://www.businesswire.com/news/home/20250527974928/en/



Permalink

https://www.aetoswire.com/en/news/2705202546972


Contacts

Press Contact:

Sawa Himeno

Head of Communications Dept., Rigaku Holdings Corporation

prad@rigaku.co.jp

+81 90 6331 9843

MAG GROUP and Citic Limited Sign MoU for USD 6 Billion "Keturah Ardh" Development in Dubai

Dubai, United Arab Emirates - Wednesday, 28. May 2025


CITIC Limited's total assets exceed USD 1.67 trillion

 


In a landmark move poised to significantly shape Dubai's luxury real estate landscape, MAG Group and CITIC Limited, one of China's largest state-owned conglomerates, have announced the signing of a Memorandum of Understanding (MoU) for the development of Keturah Ardh — a visionary USD 6 billion project spanning 18.47 million square feet in the Al Rowaiyah First District of Dubai.


The signing ceremony brought together two financial powerhouses: MAG Group Holding, with a portfolio valued at USD 3 billion, ongoing sales worth USD 5 billion, and developments estimated at approximately USD 17 billion; and CITIC Limited, which manages total assets exceeding USD 1.67 trillion. This collaboration, marking CITIC Limited's first major entry into Dubai's premium real estate sector.


The development timeline outlines the completion of infrastructure works and full site mobilisation by Q2 and Q3 2025. The first phase, launched under the Keturah Ardh Couture Art brand, will debut in Q4 2025. The second phase is expected in Q1 2026, with subsequent phases rolled out through to 2027. The project is expected to be completed within a two- to seven-year timeframe.


Plot sizes within the development will range from 50,000 to 200,000 square feet, and the site will feature more than 100,000 trees—aging between 20 and 2,200 years—brought together through an innovative 'Life-Scaping' approach.


In his comments, Moafaq A. Al Gaddah, Founder and Chairman of MAG Group Holding, said: "Keturah Ardh exemplifies what the future of living in Dubai should look like. Our aim is to create a place where people feel deeply connected to their surroundings, with nature and community embedded into daily life."


Yang Jianqiang, Chairman of CITIC Limited, said: "Our partnership with MAG Group Holding is built on a strategy of long-term value and genuine collaboration. By leveraging CITIC Limited's wealth of expertise in advanced manufacturing, innovative materials, sustainable infrastructure, and real estate, we want to shape a destination that welcomes all generations and sets new benchmarks for sustainability in the region."


In line with international environmental standards, the project is actively pursuing prestigious certifications such as LEED ND and the WELL Building Standard—underscoring Dubai's commitment to sustainable and future-ready developments.



Permalink

https://www.aetoswire.com/en/news/mag2852025en


Contacts

Khaled Abu Hishme

khaled@cbpr.me

Supreme Court of Georgia Dismisses SPRIBE’s Appeal, Solidifying Aviator LLC’s IP Victory


 TBILISI, Georgia 

(BUSINESS WIRE) -- On May 20, 2025, the Supreme Court of Georgia dismissed SPRIBE’s appeal as inadmissible, thereby finalizing the invalidation of SPRIBE’s trademarks in Georgia. The court confirmed that SPRIBE’s trademarks were registered in bad faith and in violation of Aviator LLC’s copyright. This ruling marks a significant milestone for Aviator LLC in its global intellectual property enforcement efforts, particularly as Georgia—the country of origin of the Aviator IP—has now formally recognized Aviator LLC as the rightful owner of both the Aviator trademark and the associated airplane image.


The decision delivers a strategic victory to Aviator LLC, strengthening its legal position in related disputes unfolding across multiple jurisdictions. The recognition of Aviator LLC’s exclusive IP rights in its home country may serve as a persuasive precedent in ongoing proceedings elsewhere.


One such key proceeding is currently underway at the European Union Intellectual Property Office (EUIPO), where Aviator LLC has filed for the invalidation of SPRIBE’s Aviator trademarks. SPRIBE has thus far requested three separate deadline extensions for filing a response—an apparent attempt to delay the case and avoid addressing the underlying allegation: the unauthorized registration of third-party intellectual property in the European market.


For further information and media queries, please contact Aviator LLC’s representatives at info.aviator@mikadze.ge.


 


View source version on businesswire.com: https://www.businesswire.com/news/home/20250526014342/en/



Permalink

https://www.aetoswire.com/en/news/2705202546947


Contacts

Nikoloz Gogilidze

info.aviator@mikadze.ge


 

Takeda and Nature Announce Call for Applications Now Open for 2026 Innovators in Science Award

 OSAKA, Japan & CAMBRIDGE, Mass. - Tuesday, 27. May 2025



− Award supports emerging biomedical researchers globally focused on gastrointestinal and inflammatory diseases, neuroscience and oncology


(BUSINESS WIRE) -- Takeda (TSE:4502/NYSE:TAK) today announced that applications are now open for its Innovators in Science Award. This prestigious global award, originally launched in 2016, celebrates groundbreaking research with a focus on emerging scientific leaders who are advancing the frontiers of scientific discovery and fostering innovation that has the potential to transform lives.


In 2026, the Takeda Innovators in Science Award with Nature will recognize promising early-career scientists in the areas of gastrointestinal and inflammatory diseases, neuroscience, and oncology. Takeda will award three category winners – one from each area of focus – with a $75,000 prize. One grand prize winner, to be announced live at the Innovators in Science Award gala on April 9, 2026, will also receive an additional $175,000 award, for a total grand prize of $250,000.


To address challenges that are unique to emerging scientists, category winners and shortlisted applicants will be invited to participate in a 12-month career development program administered by Nature. The program will offer training to develop skills such as grant writing, research communication and lab management. Winners will also have access to mentorship opportunities.


As one of the largest prizes of its kind, the Innovators in Science Award reinforces Takeda’s commitment to promoting scientific excellence and fostering a culture of partnership between industry and academia.


“Since 2016, our Innovators in Science Award has uplifted researchers who are not afraid of asking big questions, thinking outside the box and doggedly pursuing discoveries to advance science,” said Andrew Plump, M.D., Ph.D., president of R&D at Takeda. “We are proud to shine a spotlight on rising scientists who are driving bold, transformative breakthroughs in their fields. Through funding, mentorship, and collaboration opportunities, we aim to support their continued professional growth.”


Springer Nature will independently administer the award on behalf of Takeda, with responsibility for reviewing applications and selecting judges and winners.


“For 150 years, Nature has earned the trust of the global research community by publishing groundbreaking advances across all areas of science and technology. We recognize the vital contributions of early-career researchers and are committed to supporting their growth and success,” added Nature’s publisher Richard Hughes. “We are proud to partner with Takeda on the Innovators in Science Award—an initiative designed to celebrate and elevate the work of exceptional early-career scientists. We invite researchers around the world to apply, and we remain dedicated to providing a rigorous evaluation process and amplifying the voices and achievements of the award winners across our platforms."


The Call for Applications is now open at https://www.innovatorsinscienceaward.com/ and will remain open through September 16, 2025. Shortlisted applicants will be announced in January 2026 and category winners will be announced in February 2026, ahead of the live grand prize announcement at the gala on April 9, 2026, in Boston.


About the Innovators in Science Award

Launched in 2016, the Takeda Innovators in Science Award provides scientific leaders with the support and recognition needed to drive bold, transformative breakthroughs in their fields. Since its inception, the award has celebrated the outstanding contributions of 10 established and early career researchers with $2M of unrestricted funding. This global award recognizes researchers who are advancing the frontiers of scientific discovery, fostering innovation that has the potential to transform lives. In 2026, the Innovators in Science Award honors groundbreaking research by early career scientists in gastrointestinal and inflammatory diseases, neuroscience and oncology. Past winners include: Elham Azizi, Ph.D., for her innovative models that helped identify determinants of immunotherapy response in leukemia for the first time; Elaine Y. Hsiao, Ph.D., for her discoveries of how the gut microbiome influences the brain and behavior; and Viviana Gradinaru, Ph.D., for enabling targeted gene delivery across the blood-brain barrier for research and clinical purposes. For more information, visit https://innovatorsinscienceaward.com


About Takeda

Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit www.takeda.com.


Important Notice

For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.


The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.


Forward-Looking Statements

This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could”, “anticipates”, “estimates”, “projects” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations, including global health care reforms; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s); and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/sec-filings-and-security-reports/ or at www.sec.gov. Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.


 


View source version on businesswire.com: https://www.businesswire.com/news/home/20250527716937/en/



Permalink

https://aetoswire.com/en/news/2705202546962


Contacts

Media Contacts:


Japanese Media

Yuko Yoneyama

yuko.yoneyama@takeda.com


U.S. and International Media

Chris Stamm

chris.stamm@takeda.com


 

US Food and Drug Administration (FDA) Grants Interchangeability Designation to Samsung Bioepis and Organon HADLIMA™ (adalimumab-bwwd) Injection

 HADLIMA™ (adalimumab-bwwd) injection, 40 mg/0.4 mL & 40 mg/0.8 mL is now interchangeable with all high- and low-concentration presentations (autoinjector, prefilled syringe, and single-dose vial) of Humira (adalimumab)1,2


The interchangeability designation for HADLIMA is based on a Pharmacokinetics, Efficacy, Safety, and Immunogenicity study of SB5 versus Humira in patients with moderate to severe chronic plaque psoriasis3

An interchangeable biosimilar product may be substituted for the reference product without consulting the prescriber, subject to state pharmacy laws4

 


(BUSINESS WIRE) -- Samsung Bioepis Co., Ltd. and Organon & Co. (NYSE: OGN) today announced that the US Food and Drug Administration (FDA) has designated the HADLIMA™ (adalimumab-bwwd) high- and low-concentration (40 mg/0.4 mL, 40 mg/0.8 mL) autoinjectors and high-concentration prefilled syringe as interchangeable biosimilars to Humira® (adalimumab).2 These interchangeability designations follow the interchangeability designation received for the HADLIMA low-concentration (40 mg/0.8 mL) prefilled syringe and single-dose vial in June 2024.1 With today’s additional interchangeability designations, HADLIMA is now interchangeable with all presentations of the reference product.1,2 An interchangeability designation enables a pharmacist to substitute the reference product with a biosimilar without the need to consult the prescriber, depending on state pharmacy laws.4


“An increased uptake of biosimilars may lead to improved patient access to biologic therapies and potential savings for the US health care system.5 As a company dedicated to making medicines more accessible, HADLIMA, now designated as fully interchangeable with the reference product, has a greater potential to bring savings for patients.1,2,5 As our data shows, on average, patients paid more than four times as much out of pocket per month for Humira compared to HADLIMA,”*6 said Jon Martin, US Commercial Lead, Biosimilars and Established Brands at Organon. “With this approval, pharmacies can substitute HADLIMA for the reference product Humira without consulting prescribers (subject to state law), which may facilitate increased access for patients to receive the medications they need.”4,5


“This designation is meaningful as it signifies our continued commitment to making biosimilars more accessible. Both biosimilars and interchangeable biosimilars are highly similar and have no clinically meaningful differences in safety, purity, and potency compared to the reference product,”7 said Byoung In Jung, Vice President and Regulatory Affairs Team Leader at Samsung Bioepis. “With this designation, we continue to benefit patients, health care providers, and health care systems around the world.”


HADLIMA is a tumor necrosis factor (TNF) blocker indicated for appropriate patients with rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and uveitis. See full indications below. Patients treated with adalimumab products, including HADLIMA, are at increased risk for developing serious infections that may lead to hospitalization or death. Discontinue HADLIMA if a patient develops a serious infection or sepsis. Monitor patients closely for the development of signs and symptoms of infection during and after treatment with HADLIMA, including the possible development of tuberculosis (TB) in patients who tested negative for latent TB infection prior to initiating therapy. Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers including adalimumab products. See additional safety information below.


The interchangeability designation was based on clinical data from a randomized, double-blind, 1:1 ratio, parallel-group, multiple-dose clinical trial, which assessed pharmacokinetics (PK), efficacy, safety, and immunogenicity in two treatment groups: patients with moderate to severe plaque psoriasis who switched between formulations of EU-sourced Humira and high-concentration SB5 (adalimumab biosimilar) versus patients receiving Humira continuously. The study demonstrated comparability in terms of primary PK endpoints, as well as efficacy, safety, and immunogenicity profiles between the switching group and continuous Humira treatment group.3 In addition, data from additional studies provide further evidence to support the interchangeability designation for HADLIMA low- and high-concentration autoinjectors.8


HADLIMA was first approved by the FDA in 2019 as a low-concentration (40 mg/0.8 mL) formulation of prefilled syringe and autoinjector. The high-concentration (40 mg/0.4 mL) formulation of prefilled syringe and autoinjector of HADLIMA was approved in 2022.9 Both low- and high-concentration formulations of HADLIMA have been commercially available in the US market since 2023.10


About HADLIMA™ (adalimumab-bwwd) Injection


HADLIMA is a tumor necrosis factor (TNF) blocker indicated for:


Rheumatoid Arthritis: HADLIMA is indicated, alone or in combination with methotrexate or other non-biologic disease-modifying antirheumatic drugs (DMARDs), for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis.


Juvenile Idiopathic Arthritis: HADLIMA is indicated, alone or in combination with methotrexate, for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older.


Psoriatic Arthritis: HADLIMA is indicated, alone or in combination with non-biologic DMARDs, for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis.


Ankylosing Spondylitis: HADLIMA is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis.


Crohn’s Disease: HADLIMA is indicated for the treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older.


Ulcerative Colitis: HADLIMA is indicated for the treatment of moderately to severely active ulcerative colitis in adult patients.

Limitations of Use:

The effectiveness of HADLIMA has not been established in patients who have lost response to or were intolerant to tumor necrosis factor (TNF) blockers.


Plaque Psoriasis: HADLIMA is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. HADLIMA should only be administered to patients who will be closely monitored and have regular follow-up visits with a physician.


Hidradenitis Suppurativa: HADLIMA is indicated for the treatment of moderate to severe hidradenitis suppurativa in adult patients.


Uveitis: HADLIMA is indicated for the treatment of non-infectious intermediate, posterior, and panuveitis in adult patients.


SELECTED SAFETY INFORMATION


SERIOUS INFECTIONS


Patients treated with adalimumab products, including HADLIMA, are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids.


Discontinue HADLIMA if a patient develops a serious infection or sepsis.


Reported infections include:


Active tuberculosis (TB), including reactivation of latent TB. Patients with TB have frequently presented with disseminated or extrapulmonary disease. Test patients for latent TB before HADLIMA use and during therapy. Initiate treatment for latent TB prior to HADLIMA use.


Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized, disease. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Consider empiric anti-fungal therapy in patients at risk for invasive fungal infections who develop severe systemic illness.


Bacterial, viral, and other infections due to opportunistic pathogens, including Legionella and Listeria.


Carefully consider the risks and benefits of treatment with HADLIMA prior to initiating therapy in patients:


with chronic or recurrent infection


who have been exposed to TB


with a history of opportunistic infection


who resided in or traveled in regions where mycoses are endemic


with underlying conditions that may predispose them to infection


Monitor patients closely for the development of signs and symptoms of infection during and after treatment with HADLIMA, including the possible development of TB in patients who tested negative for latent TB infection prior to initiating therapy.


Do not start HADLIMA during an active infection, including localized infections.


Patients older than 65 years, patients with co-morbid conditions, and/or patients taking concomitant immunosuppressants may be at greater risk of infection.


If an infection develops, monitor carefully and initiate appropriate therapy.


Drug interactions with biologic products: A higher rate of serious infections has been observed in rheumatoid arthritis (RA) patients treated with rituximab who received subsequent treatment with a TNF blocker. An increased risk of serious infections has been seen with the combination of TNF blockers with anakinra or abatacept, with no demonstrated added benefit in patients with RA. Concomitant administration of HADLIMA with other biologic DMARDs (eg, anakinra or abatacept) or other TNF blockers is not recommended based on the possible increased risk for infections and other potential pharmacological interactions.


MALIGNANCY


Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, including adalimumab products. Postmarketing cases of hepatosplenic T-cell lymphoma (HSTCL), a rare type of T-cell lymphoma, have been reported in patients treated with TNF blockers, including adalimumab products. These cases have had a very aggressive disease course and have been fatal. The majority of reported TNF blocker cases have occurred in patients with Crohn’s disease or ulcerative colitis and the majority were in adolescent and young adult males. Almost all of these patients had received treatment with azathioprine or 6-mercaptopurine concomitantly with a TNF blocker at or prior to diagnosis. It is uncertain whether the occurrence of HSTCL is related to use of a TNF blocker or a TNF blocker in combination with these other immunosuppressants.


Consider the risks and benefits of HADLIMA treatment prior to initiating or continuing therapy in a patient with known malignancy.


In clinical trials, more cases of malignancies were observed among adalimumab-treated patients compared to control patients.


Non-melanoma skin cancer (NMSC) was reported during clinical trials for adalimumab-treated patients. Examine all patients, particularly those with a history of prolonged immunosuppressant or psoralen and ultraviolet A (PUVA) therapy, for the presence of NMSC prior to and during treatment with HADLIMA.


In adalimumab clinical trials, there was an approximate 3-fold higher rate of lymphoma than expected in the general U.S. population. Patients with chronic inflammatory diseases, particularly those with highly active disease and/or chronic exposure to immunosuppressant therapies, may be at higher risk of lymphoma than the general population, even in the absence of TNF blockers.


Postmarketing cases of acute and chronic leukemia were reported with TNF blocker use. Approximately half of the postmarketing cases of malignancies in children, adolescents, and young adults receiving TNF blockers were lymphomas; other cases included rare malignancies associated with immunosuppression and malignancies not usually observed in children and adolescents.


HYPERSENSITIVITY


Anaphylaxis and angioneurotic edema have been reported following adalimumab administration. If a serious allergic reaction occurs, stop HADLIMA and institute appropriate therapy.


HEPATITIS B VIRUS REACTIVATION


Use of TNF blockers, including HADLIMA, may increase the risk of reactivation of hepatitis B virus (HBV) in patients who are chronic carriers. Some cases have been fatal.


Evaluate patients at risk for HBV infection for prior evidence of HBV infection before initiating TNF blocker therapy.


Exercise caution in patients who are carriers of HBV and monitor them during and after HADLIMA treatment.


Discontinue HADLIMA and begin antiviral therapy in patients who develop HBV reactivation. Exercise caution when resuming HADLIMA after HBV treatment.


NEUROLOGIC REACTIONS


TNF blockers, including adalimumab products, have been associated with rare cases of new onset or exacerbation of central nervous system and peripheral demyelinating diseases, including multiple sclerosis, optic neuritis, and Guillain-Barré syndrome.


Exercise caution when considering HADLIMA for patients with these disorders; discontinuation of HADLIMA should be considered if any of these disorders develop.


HEMATOLOGIC REACTIONS


Rare reports of pancytopenia, including aplastic anemia, have been reported with TNF blockers. Medically significant cytopenia has been infrequently reported with adalimumab products.


Consider stopping HADLIMA if significant hematologic abnormalities occur.


CONGESTIVE HEART FAILURE


Worsening and new onset congestive heart failure (CHF) has been reported with TNF blockers. Cases of worsening CHF have been observed with adalimumab products; exercise caution and monitor carefully.


AUTOIMMUNITY


Treatment with adalimumab products may result in the formation of autoantibodies and, rarely, in development of a lupus-like syndrome. Discontinue treatment if symptoms of a lupus-like syndrome develop.


IMMUNIZATIONS


Patients on HADLIMA should not receive live vaccines.


Pediatric patients, if possible, should be brought up to date with all immunizations before initiating HADLIMA therapy.


Adalimumab is actively transferred across the placenta during the third trimester of pregnancy and may affect immune response in the in utero-exposed infant. The safety of administering live or live-attenuated vaccines in infants exposed to adalimumab products in utero is unknown. Risks and benefits should be considered prior to vaccinating (live or live-attenuated) exposed infants.


ADVERSE REACTIONS


The most common adverse reactions in adalimumab clinical trials (>10%) were: infections (eg, upper respiratory, sinusitis), injection site reactions, headache, and rash.


Before prescribing HADLIMA, please read the Prescribing Information, including the Boxed Warning about serious infections and malignancies. The Medication Guide and Instructions for Use also are available.


To learn more about HADLIMA, please visit www.hadlima.com. Healthcare providers can learn more about HADLIMA at www.HADLIMAPro.com.


About Samsung Bioepis Co., Ltd.


Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing health care that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world's leading biopharmaceutical company. Samsung Bioepis continues to advance a broad pipeline of biosimilar candidates that cover a spectrum of therapeutic areas, including immunology, oncology, ophthalmology, hematology, nephrology, and endocrinology. For more information, please visit: www.samsungbioepis.com and follow us on social media – X, LinkedIn.


About Organon


Organon is an independent global healthcare company with a mission to help improve the health of women throughout their lives. Organon’s diverse portfolio offers over 70 medicines and products in women’s health, biosimilars, and a large franchise of established medicines across a range of therapeutic areas. In addition to Organon’s current products, the company invests in innovative solutions and research to drive future growth opportunities in women’s health and biosimilars. Organon is also pursuing opportunities to collaborate with biopharmaceutical partners and innovators who look to commercialize their products by leveraging Organon’s scale and agile presence in fast growing international markets.


Organon has geographic scope with significant reach, world-class commercial capabilities, and approximately 10,000 employees with headquarters located in Jersey City, New Jersey.


For more information, visit http://www.organon.com and connect with us on LinkedIn, Instagram, X (formerly known as Twitter) and Facebook.


About the Samsung Bioepis-Organon Collaboration


HADLIMA is developed, manufactured and supplied by Samsung Bioepis, and commercialized by Organon. Samsung Bioepis and Organon have development and commercialization collaborations for two immunology products and one oncology product in the United States.


© 2025 Organon group of companies. All rights reserved. ORGANON and the ORGANON Logo are trademarks of the Organon group of companies.


HUMIRA is a trademark registered in the US by AbbVie Biotechnology Ltd.; Organon is not associated with this trademark owner.


Cautionary Note Regarding Forward-Looking Statements


Except for historical information, this press release includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including, but not limited to, statements about the potential benefits of biosimilars, as well as Organon’s and Samsung’s collaboration and the benefits thereof. Forward-looking statements may be identified by words such as “may,” “potential,” “can,” “should,” “continue,” “will,” “expects,” “future,” “opportunity,” or words of similar meaning. These statements are based upon the current beliefs and expectations of Organon’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate, or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Risks and uncertainties include, but are not limited to, expanded brand and class competition in the markets in which Organon operates; trade protection measures and import or export licensing requirements, including the direct and indirect impacts of tariffs (including any potential pharmaceutical sector tariffs), trade sanctions or similar restrictions by the United States or other governments; changes in U.S. and foreign federal, state and local governmental funding allocations including the timing and amounts allocated to Organon’s customers and business partners; economic factors over which Organon has no control, including changes in inflation, interest rates, recessionary pressures, and foreign currency exchange rates; market volatility, downgrades to the U.S. government’s sovereign credit rating or its perceived creditworthiness, changing political or geopolitical conditions, market contraction, boycotts, and sanctions, as well as Organon’s ability to successfully manage uncertainties related to the foregoing; difficulties with performance of third parties Organon relies on for its business growth; the failure of any supplier to provide substances, materials, or services as agreed; the increased cost of supply, manufacturing, packaging, and operations; difficulties developing and sustaining relationships with commercial counterparties; restructurings or other disruptions at the FDA, the U.S. Securities and Exchange Commission (“SEC”) and other U.S. and comparable government agencies; pricing pressures globally, including rules and practices of managed care groups, judicial decisions and governmental laws and regulations related to Medicare, Medicaid and health care reform, pharmaceutical reimbursement and pricing in general; the impact of higher selling and promotional costs; changes in government laws and regulations in the United States and other jurisdictions, including laws and regulations governing the research, development, approval, clearance, manufacturing, supply, distribution, and/or marketing of Organon’s products and related intellectual property, environmental regulations, and the enforcement thereof affecting Organon’s business; efficacy, safety or other quality concerns with respect to Organon’s marketed products, whether or not scientifically justified, leading to product recalls, withdrawals or declining sales; future actions of third parties, including significant changes in customer relationships or changes in the behavior and spending patterns of purchasers of health care products and services, including delaying medical procedures, rationing prescription medications, reducing the frequency of physician visits and forgoing health care insurance coverage; legal factors that could preclude commercialization of products or negatively affect the profitability of existing products; the failure by Organon or its third party collaborators and/or their suppliers to fulfill our or their regulatory or quality obligations, which could lead to a delay in regulatory approval or commercial marketing of Organon’s products; and volatility of commodity prices, fuel, shipping rates that impact the costs and/or ability to supply Organon’s products. Organon undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in Organon’s filings with the SEC, including Organon’s most recent Annual Report on Form 10-K and subsequent SEC filings, available at the SEC’s Internet site (www.sec.gov).


*Based on an analysis of actual patient claims processed from July 2023 to August 2024, with the average out-of-pocket costs being $215 vs $48 for HUMIRA and HADLIMA, respectively.


1 Approval letter for HADLIMA (adalimumab-bwwd) supplemental biologics license application 761059/S-018. U.S. Food and Drug Administration. June 2024.


2 Approval letter for HADLIMA (adalimumab-bwwd) supplemental biologics license applications 761059/S-025 and 761059/S-026. U.S. Food and Drug Administration. May 2025.


3 Feldman S, Valiukeviciene S, Pulka G, et al. Interchangeability of SB5 and adalimumab reference product in patients with moderate to severe chronic plaque psoriasis. Poster presented at: American Academy of Dermatology Annual Meeting; March 8-12, 2024; San Diego, CA. Accessed May 2025. https://eposters.aad.org/abstracts/50522


4 US Food and Drug Administration. Biosimilar and interchangeable biologics; more treatment choices. Updated August 17, 2023. Accessed May 14, 2025. https://www.fda.gov/consumers/consumer-updates/biosimilar-and-interchangeable-biologics-more-treatment-choices


5 Aitken M, Kleinrock M, Pritchett J. Biosimilars in the United States 2023-2027: competition, savings, and sustainability. IQVIA Institute for Human Data Science. January 31, 2023. Accessed March 5, 2025. https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/biosimilars-in-the-united-states-2023-2027


6 Data available on request from Organon Professional Services-DAP (Marketing Operations), 30 Hudson St., Jersey City, NJ 07302. Please specify information package REF-146241.


7 Biosimilars: Review and approval. US Food and Drug Administration. December 13, 2022. Accessed May 16, 2025. https://www.fda.gov/drugs/biosimilars/review-and-approval


8 Data on File. Organon group of companies.


9 Approval letter for HADLIMA (adalimumab-bwwd) supplemental biologics license application 761059/S-005. U.S. Food and Drug Administration. August 2022.


10 Organon & Samsung Bioepis announce US launch of HUMIRA biosimilar HADLIMA™ (adalimumab-bwwd) in multiple presentations consistent with originator. Organon. July 1, 2023. Accessed May 22, 2025. https://www.organon.com/news/organon-samsung-bioepis-announce-us-launch-of-humira-biosimilar-hadlima-adalimumab-bwwd-in-multiple-presentations-consistent-with-originator/


 


View source version on businesswire.com: https://www.businesswire.com/news/home/20250527970852/en/



Permalink

https://www.aetoswire.com/en/news/2705202546963


Contacts

Organon Media Contacts:

Felicia Bisaro

(646) 703-1807

Kate Vossen

(732) 675-8448


Investor Contacts:

Jennifer Halchak

(201) 275-2711

Renee McKnight

(551) 204-6129


Samsung Bioepis Media Contacts:

Yoon Kim, yoon1.kim@samsung.com

Anna Nayun Kim, nayun86.kim@samsung.com

Milestone's Video Technology Powers Next-Gen AI for Smart Cities




 Open platform unlocks trusted video data and best-in-class video analytics for smarter, safer cities

 

Dubai is expanding its innovative work in developing artificial intelligence-powered traffic technology through its AI Strategy 2030, looking to transform urban mobility through advanced AI traffic control systems, directed by the Roads and Transport Authority (RTA).

A new opportunity is now emerging for smart cities like Dubai. Milestone Systems has launched Project Hafnia - a collaborative project aimed at building a compliant data library and creating high-performing AI models, so-called visual language models.

The future of smart city technology and transformation of urban mobility and safety isn't being shaped in Silicon Valley — it's taking root in the small US city of Dubuque, Iowa. The city has become a live testbed for AI-driven traffic management thanks to the unique public-private collaboration led by Milestone Systems under Project Hafnia.

Challenge: High-Potential AI, Low-Quality Data

Despite extensive camera deployments, cities often struggle to derive real-time intelligence from video. AI models trained on synthetic or generic datasets frequently underperform in complex, real-world environments. High false-positive rates make them impractical for daily operations, especially in time-critical applications like traffic management, preventing municipalities from gaining the real-time insights needed to improve mobility, safety, and emergency response.

Solution: Public-Private Innovation in Action

Project Hafnia, led by Milestone Systems, develops a high-performance, real-world AI model. Milestone led the 12-month project from initial concept to full-scale deployment, investing in cloud-based AI training and professional video annotation. Unlike conventional vendor-customer setups, this collaboration was structured with shared value in mind: each party contributed expertise, resources, and infrastructure, aligning toward a common goal.

At the heart of this success story is Milestone’s investment in creating a secure, high-quality, and legally compliant data library that supports transparency and data traceability requirements in evolving AI regulations. Milestone transformed the city’s raw traffic footage into valuable AI training material. This investment paid off dramatically, with model accuracy jumping from 80% to over 95%. Below that threshold, false positives are too frequent, undermining usability. Above it, cities unlock new levels of accuracy and insight.

Results: Scalable, Transferable, Trusted

With more than 100 traffic cameras participating in the trial, Project Hafnia validated AI performance in the field across a range of changing light, weather, and traffic patterns. The resulting platform is scalable and transferable, giving other cities a tested blueprint for AI-enhanced urban operations. AI models originally developed for traffic monitoring (vehicle classification, pedestrian tracking, anomaly detection) can now be repurposed to support public safety, emergency response, and infrastructure planning across departments.

Louise Bou Rached, Director – Middle East, Turkey and Africa, Milestone Systems, expressed, "Project Hafnia shows how a collaborative strategy and a shared dedication to data integrity can contribute to transforming urban solutions. Milestone Systems and its partners have attained unmatched model accuracy of over 95% by using real-world traffic footage and careful data annotation, thus facilitating cities like Dubuque and Dubai to deploy artificial intelligence with confidence. This project not only shows scalable and transferable technology but also opens the door for more sustainable, safer, and smarter urban mobility worldwide."

A New Framework for Public-Private Innovation

Beyond the technical achievements, the project established a new template for collaboration between cities, technology vendors, and platform providers. Rather than a traditional vendor-customer relationship, the collaboration operated on balanced value exchange principles.

The collaboration brought together diverse perspectives and created a forward-looking solution that evolved organically. From concept to working prototype to full-scale deployment, every participant helped shape the outcome.

Thomas Jensen, CEO of Milestone Systems, emphasized the broader vision: “At Milestone, we believe that AI innovation starts with trusted data and open collaboration. Project Hafnia proves that with the right platform, even mid-sized cities like Dubuque can lead the way in responsible, data-driven transformation. This is a blueprint for how cities everywhere can harness AI to improve safety, mobility, and quality of life — all while staying in control of their data.”

Project Hafnia not only demonstrated that real-world AI can work, it showed that it can scale, ethically and collaboratively.

Project Hafnia is more than a traffic management success story. It’s a living prototype of how cities — big or small — can unlock the full potential of AI by investing in data, partnerships, and transparency.



Contacts

Namita Thakkar - namita@matrixdubai.com

Tuesday, May 27, 2025

Over 53% of Emirati Jobseekers Still Operate Onsite, Highlighting Need for Flexibility in 2025



 New TASC Outsourcing and MoHRE survey reveals key trends and insightful data to help actualise Emiratisation in 2025

 

Key Highlights:

  • Despite global shifts towards flexible working models, over 53% of Emirati job seekers continue to work in fully onsite roles.
  • 52.39% of employers acknowledge facing retention challenges, and an additional 25.60% perceive these challenges as highly significant, primarily due to discrepancies in compensation packages and market realities.
  • 50% of Emirati respondents possess basic AI-related skills, the survey highlights a notable gap in advanced areas such as machine learning, natural language processing, and robotics.

 

In a country where ambition meets opportunity, the UAE continues to champion the empowerment of its people.  With a bold vision to shape a future-ready workforce, TASC Outsourcing, MENA’s leading workforce solutions provider, has once again joined forces with the Ministry of Human Resources and Emiratisation (MoHRE) to launch the 3rd edition of their flagship guidebook, "Making Emiratisation a Success – 2025." This latest edition sheds light on the nation’s impressive strides in driving meaningful employment for Emiratis and shaping a more inclusive, resilient labour market.

 

According to the survey, by the end of 2024, there was a record-breaking growth of 131,883 Emirati employees in the private sector, reflecting the success of targeted Emiratisation initiatives. This achievement was made possible through strong public-private sector collaboration and underscores the collective commitment to building a diverse and inclusive national workforce.

 

The present employment scenario for Emirati talent shows some encouraging characteristics alongside substantial challenges. Nearly half (49.13%) of the Emirati job seekers are willing to begin working within 30 days, and 82.97% express confidence in their skills for private-sector positions, suggesting a strong and assertive talent pool availability in the UAE market. Employers appear aligned with this momentum, as 63.40% continue to prioritise permanent contracts, reinforcing long-term Emiratisation goals. While job satisfaction among Emiratis stays around 57%, 74% of respondents express dissatisfaction with salaries, highlighting compensation as a key area for improvement. The shared emphasis on stability, by both employers and Emirati candidates, continues to shape hiring practices across sectors.

 

On-site work prevails, with more than half (53%) of Emirati employees fully onsite, and limited access to hybrid or remote options, highlighting the need for flexibility and talent retention, especially for women and young parents. Salary disparities, cultural imbalance, and appealing public-sector options also drive high attrition rates, with 52.39% of companies battling retention.

 

Speaking of the need for Emiratisation initiatives, Mahesh Shahdadpuri, Founder and CEO of TASC Outsourcing, stated, "Effective Emiratisation requires precise alignment between employer offerings and Emirati talent expectations. Our data-driven guidebook underscores essential strategies such as increased workplace flexibility, tailored compensation structures, and targeted skill development programmes, particularly in AI and emerging technologies. As Emiratisation continues evolving, our commitment remains firm—to support private-sector employers in creating sustainable, meaningful roles for UAE nationals."

 

The Emiratisation Guidebook 2025 offers essential data and strategic insights to enhance Emirati employee retention, promote workplace flexibility, and better align with private-sector needs. Its survey, which gathered perspectives from 2,000 Emirati job seekers and employees and 450 private-sector employers, provides valuable insights to support these objectives.

 

Emirati citizens are increasingly looking for positions in technology-centric industries, reflecting the UAE's strategic emphasis on technological innovation and digital transformation. In particular, preference for the information and communication sector has grown significantly from 4.12%  in 2024 to 15.84% this year, with continued interest in the public and social sector (33.95%). For employers, Operations (46.17%), HR & Admin (45.69%), and Sales & Marketing (44.06%) remain the top hiring categories. With 23.98% of Emirati job seekers indicating a definitive shift toward digital and tech-driven roles, the IT sector has emerged as the top employment choice among Emirati job seekers. While 52.26% have a basic understanding of AI, there is a great opportunity for upskilling in AI knowledge, especially in advanced areas such as machine learning.

 

HE Farida Abdulla Al Ali, Assistant Undersecretary of National Talents, MoHRE, emphasised, "The UAE government remains unwavering in its commitment to accelerating Emiratisation, anchored by transformative initiatives such as Nafis and robust policy frameworks that establish measurable, sector-specific hiring targets. Through stringent compliance protocols and proactive oversight, we are ensuring that Emirati talent is seamlessly and sustainably integrated into the private sector workforce. Our partnership with TASC amplifies this national mission—enabling employers to meaningfully contribute to Emiratisation objectives through various initiatives."

 

Workforce capabilities are further strengthened by supporting AI upskilling initiatives, such as those supported by MoHRE and Nafis. By increasing employer engagement, making the most of the Falak Tayyeb app for job searches may enhance hiring effectiveness and cultural fit. Furthermore, keeping up with Emiratisation regulations and examining incentive schemes, like wage support plans for recent graduates, can help guarantee adherence and promote the integration of diverse talent.

 

bout TASC Outsourcing:

Now celebrating more than 17 years of experience in providing world-class talent that growing businesses need in the UAE and across the MENA region, TASC Outsourcing is one of the leading People & compliance solution partner in the MENA region.

 

We are experts in outsourcing, recruiting, payroll management, and HR solutions. TASC's team of over 300 staff and more than 6500 associates serve 450+ existing clients, and the company has offices in Dubai, Riyadh, Abu Dhabi, Doha, and Bangalore.

 

For more information, please visit: https://tascoutsourcing.com/en



Contacts

Jazlynn Lobo: jazlynn@matrixdubai.com

Krishika Mahesh: krishika@matrixdubai.com